EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study

Bjørn Hoe iD, Sebastian M N Heimbürger, Lærke S Gasbjerg iD, Amalie R Lanng, Mads B Lynggaard, Asger B Lund, Flemming Dela, Jens Faber, Kirsa Skov-Jeppesen, Susanne Engberg, Bolette Hartmann, Jens J Holst iD und 4 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70373 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Bjørn Hoe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Diabetes Mellitus, Type 1, Hypoglycemia, Blood Glucose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In type 1 diabetes, glucose‐dependent insulinotropic polypeptide (GIP) increases glucagon secretion during low plasma glucose and improves time in the glycaemic range during daytime. To explore the glucose‐stabilising potential of GIP in type 1 diabetes, we evaluated the effects of exogenous and endogenous GIP on plasma glucose excursions in a setting of excess prandial insulin and physical activity after meal ingestion. Materials and Methods In a randomised, placebo‐controlled, double‐blind crossover design, 12 men with type 1 diabetes underwent three separate study days involving a 4.5‐h continuous intravenous infusion of GIP, the GIP receptor antagonist GIP(3‐30)NH 2 , and placebo, respectively, during which ingestion of a standardised mixed meal with subcutaneous injection of excess prandial insulin (125% of normal dose) was followed by 30 min of intermediate resistance bicycling (to increase the risk of postprandial hypoglycaemia).

Results

The GIP infusion did not protect against hypoglycaemia, but compared to GIP(3‐30)NH 2 infusion, it attenuated postprandial maximum plasma glucose by 1.5 ± 0.5 mmol/L (mean ± standard error of the mean) ( p = 0.048). GIP(3‐30)NH 2 did not exacerbate glucose excursions or risk of hypoglycaemia compared with placebo. The amount of glucose infused to avoid plasma glucose

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric Inhibitory PolypeptideDiabetes Mellitus, Type 1HypoglycemiaBlood GlucoseHumansMalePostprandial PeriodDouble-Blind MethodCross-Over StudiesAdultInsulinGlucagonHypoglycemic AgentsYoung AdultReceptors, Gastrointestinal HormoneInfusions, IntravenousPeptide Fragments

Stichwörter der Autor:innen

GIP receptorantagonistglucose‐dependent insulinotropic polypeptidehypoglycaemiatype 1 diabetes

Substanzen

Gastric Inhibitory PolypeptideBlood GlucoseInsulinGlucagonHypoglycemic AgentsReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorPeptide Fragments

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Sanos, Søborg, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk A/S, Bagsværd, Denmark.
  • Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
  • Steno Diabetes Center Copenhagen, Herlev, Denmark.

ORCID-Profile: Bjørn Hoe, Lærke S Gasbjerg, Jens J Holst, Thomas F Dejgaard, Filip K Knop

Förderung

  • Leona M. and Harry B. Helmsley Charitable Trust

Zitieren

APA

Hoe, B., Heimbürger, S. M. N., Gasbjerg, L. S., Lanng, A. R., Lynggaard, M. B., Lund, A. B., Dela, F., Faber, J., Skov-Jeppesen, K., Engberg, S., Hartmann, B., Holst, J. J., Vilsbøll, T., Christensen, M. B., Dejgaard, T. F., & Knop, F. K. (2026). Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70373

Vancouver

Hoe B, Heimbürger SMN, Gasbjerg LS, Lanng AR, Lynggaard MB, Lund AB, et al. Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70373

BibTeX
@article{Hoe2026,
  author = {Hoe, Bjørn and Heimbürger, Sebastian M N and Gasbjerg, Lærke S and Lanng, Amalie R and Lynggaard, Mads B and Lund, Asger B and Dela, Flemming and Faber, Jens and Skov-Jeppesen, Kirsa and Engberg, Susanne and Hartmann, Bolette and Holst, Jens J and Vilsbøll, Tina and Christensen, Mikkel B and Dejgaard, Thomas F and Knop, Filip K},
  title = {Glucose‐dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes—A randomised placebo‐controlled study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70373}
}
Kostenlos starten →